Epidermal growth factor-stimulated human cervical cancer cell growth is associated with EGFR and cyclin D1 activation, independent of COX-2 expression levels
Open Access
- 22 September 2011
- journal article
- retracted article
- Published by Spandidos Publications in International Journal of Oncology
- Vol. 40 (1) , 13-20
Abstract
Cervical cancer constitutes the second most common cancer in women. It is evident from earlier studies that epidermal growth factor (EGF) is a mitogen, in that it mimics the function of estrogen by mediating cross-talk with other oncoproteins. Although epidermal growth factor receptor (EGFR) is highly expressed in breast and ovarian tumor tissues, its regulation by the exogenous source of its ligand EGF in human papillomavirus (HPV)-associated cervical cancer remains unclear. In this study, we addressed the question of whether EGF is required for the proliferation of HPV-positive cervical cancer cells and what mechanisms are involved. To determine this, we conducted a series of studies using HPV-positive human cervical cancer cells, CaSki and HeLa, and stimulated the cells with EGF. Our findings suggest that 6 h of stimulation with 10 ng/ml of EGF is sufficient to induce cell cycle progression associated with a significant increase in DNA synthesis, EGFR, COX-2 and cyclin D1 levels. Consistently, cellular localization and Western blot analysis for p-EGFR (Try-1045) protein showed an increase after EGF stimulation. Using siRNA gene knockdown assays we have shown that cyclin D1 siRNA has a significant negative effect on EGFR and inhibit cell growth independent of COX-2 levels. In summary, our findings reveal that an exogenous EGF stimulation may enhance HPV-related cervical cancer cell proliferation by activating EGFR and cyclin D1 that is independent of COX-2 levels, suggesting that the inhibitors of EGFR and cyclin D1 may be effective against cervical cancer cell proliferation.Keywords
This publication has 17 references indexed in Scilit:
- Involvement of NF- B and AP-1 in COX-2 upregulation by human papillomavirus 16 E5 oncoproteinCarcinogenesis, 2009
- Combination of an EGFR blocker and a COX‐2 inhibitor for the treatment of advanced cutaneous squamous cell carcinomaJDDG: Journal der Deutschen Dermatologischen Gesellschaft, 2008
- Characterization of the expression and activation of the epidermal growth factor receptor in squamous cell carcinoma of the skinBritish Journal of Dermatology, 2006
- RNA interference–mediated cyclooxygenase-2 inhibition prevents prostate cancer cell growth and induces differentiation: modulation of neuronal protein synaptophysin, cyclin D1, and androgen receptorMolecular Cancer Therapeutics, 2006
- Bidirectional Signaling between the Estrogen Receptor and the Epidermal Growth Factor ReceptorMolecular Endocrinology, 2003
- Cell Cycle Aberrations in the Pathogenesis of Squamous Cell Carcinoma of the Uterine CervixGynecologic Oncology, 2001
- Amplification and overexpression of the cyclin D1 and epidermal growth factor receptor genes in non-small-cell lung cancerJournal of Cancer Research and Clinical Oncology, 1999
- Subsets of Epidermal Growth Factor Receptors during Activation and EndocytosisJournal of Biological Chemistry, 1997
- Controlling Epidermal Growth Factor (EGF)-stimulated Ras Activation in Intact Cells by a Cell-permeable Peptide Mimicking Phosphorylated EGF ReceptorJournal of Biological Chemistry, 1996
- Stimulation of prostaglandin E2 synthesis in cloned osteoblastic cells of mouse (MC3T3-E1) by epidermal growth factor.Journal of Biological Chemistry, 1986